FDA Outlines ANDA Reconsideration Procedures

Drug Industry Daily
A A
The FDA has formalized its guidelines for sponsors seeking reconsideration of scientific or regulatory issues early in the approval process for generic drugs, issuing a guidance that also affirms the agency’s response-time pledges.

To View This Article:

Login

Subscribe To Drug Industry Daily